A multi-route model of nicotine-cotinine pharmacokinetics, pharmacodynamics and brain nicotinic acetylcholine receptor binding in humans

Regulatory Toxicology and Pharmacology

Volumn 65, Issue 1, 2013, Pages 12-28

  Teeguarden, Justin G ^a   Housand, Conrad J ^b   Smith, Jordan N ^a   Hinderliter, Paul M ^a   Gunawan, Rudy ^c   Timchalk, Charles A ^a  

^a BATTELLE MEMORIAL INSTITUTE   (United States)

^b Aegis Technologies   (United States)

^c PHARSIGHT CORPORATION   (United States)

Author keywords

Bayesian optimization; Nicotine; PBPK; Receptor binding

Indexed keywords

COTININE; NICOTINE; NICOTINIC RECEPTOR;

ARTICLE; BAYES THEOREM; BRAIN; CALIBRATION; EXPOSURE; HEART OUTPUT; HEART RATE; HUMAN; KIDNEY CLEARANCE; METABOLIC PARAMETERS; METABOLISM; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; RECEPTOR OCCUPANCY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SMOKING;

ANIMALS; BAYES THEOREM; BRAIN; COTININE; HEART RATE; HUMANS; MODELS, BIOLOGICAL; NICOTINE; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC; RISK ASSESSMENT; SMOKING; TISSUE DISTRIBUTION;

NICOTIANA TABACUM;

EID: 84871425664     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2012.10.007     Document Type: Article

References (66)

1. Andersson K., Arner P. Systemic nicotine stimulates human adipose tissue lipolysis through local cholinergic and catecholaminergic receptors. International Journal of Obesity 2001, 25:1225-1232.
2. Armitage A.K., et al. Absorption and metabolism of nicotine from cigarettes. British Medical Journal 1975, 4:313-316.
3. Benowitz N.L. Clinical pharmacology of nicotine. Annual Review of Medicine 1986, 37:21-32.
4. Benowitz, N.L., 2001. Compensatory smoking of low-yield cigarettes. Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. NCI Tobacco Control Monograph 13. National Cancer Institute, Rockville, Maryland 20852, pp. 39-64.
5. Benowitz, N.L., 2001. Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. In: U.S. Department of Health and Human Services, P.H.S., Health, N.I.O., (Eds.), vol. Monograph 13. National Cancer Institute, pp. 39-79.
6. Benowitz N.L., Henningfield J.E. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. New England Journal of Medicine 1994, 331:123-125.
7. Benowitz N.L., Jacob P. Nicotine renal excretion rate influences nicotine intake during cigarette-smoking. Journal of Pharmacology and Experimental Therapeutics 1985, 234:153-155.
8. Benowitz N.L., et al. Influence of nicotine on cardiovascular and hormonal effects of cigarettes smoking. Clinical Pharmacology & Therapeutics 1984, 36:74-81.
9. Benowitz N.L., et al. Reduced tar, nicotine, and carbon monoxide exposure while smoking ultralow - but not low-yield cigarettes. JAMA 1986, 256:241-246.
10. Benowitz N.L., et al. Stable isotope method for studying transdermal drug absorption: the nicotine patch. Clinical Pharmacology and Therapeutics 1991, 50:286-293.
11. Benowitz N.L., et al. Nicotine metabolic profile in man - comparison of cigarette-smoking and transdermal nicotine. Journal of Pharmacology and Experimental Therapeutics 1994, 268:296-303.
12. Benowitz N.L., et al. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. Journal of the National Cancer Institute 2002, 94:108-115.
13. Benowitz N.L., et al. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clinical Pharmacology & Therapeutics 2006, 80:457-467.
14. Benowitz N.L., et al. Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiology, Biomarkers & Prevention 2007, 16:2479-2485.
15. Benwell M.E.M., et al. Evidence that tobacco smoking increases the density of (-)-H-3 nicotine binding-sites in human-brain. Journal of Neurochemistry 1988, 50:1243-1247.
16. Bois F.Y. Analysis of PBPK models for risk characterization. Annals of the New York Academy of Sciences 1999, 895:317-337.
17. Bois F., et al. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 2010, 278:256-267.
18. Bois F.Y., et al. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 2010, 278:256-267.
19. Bucher J., et al. A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes. BMC Systems Biology 2011, 5:66.
20. Burns D.M., et al. Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization TobReg proposal. Tobacco Control 2008, 17:132-141.
21. Chen H.S., Gross J.F. Estimation of tissue-to-plasma partition coefficients used in physiological pharmacokinetic models. Journal of Pharmacokinetics and Biopharmaceutics 1979, 7:117-125.
22. Choi J.H., et al. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine & Tobacco Research 2003, 5:635-644.
23. Clewell H.J., Andersen M.E. Applying mode of action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene. Critical Reviews in Toxicology 2004, 34:385-445.
24. Clewell R.A., Clewell H.J. Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regulatory Toxicology and Pharmacology 2008, 50:129-143.
25. Clewell H.J., et al. A physiologically based pharmacokinetic model for retinoic acid and its metabolites. Journal of the American Academy of Dermatology 1997, 36:S77-S85.
26. Dallery J., et al. Effects of cigarette nicotine content and smoking pace on subsequent craving and smoking. Psychopharmacology (Berlin) 2003, 165:172-180.
27. David R.M., et al. Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations. Regulatory Toxicology and Pharmacology 2006, 45:55-65.
28. Dwyer J.B., et al. The dynamic effects of nicotine on the developing brain. Pharmacology & Therapeutics 2009, 122:125-139.
29. Feyerabend C., et al. Nicotine pharmacokinetics and its application to intake from smoking. British Journal of Clinical Pharmacology 1985, 19:239-247.
30. Gelman A., Rubin D.B. Markov Chain Monte Carlo methods in biostatistics. Statistical Methods in Medical Research 1996, 5:339-355.
31. Harris J.E. Incomplete compensation does not imply reduced harm: yields of 40 smoke toxicants per milligram nicotine in regular filter versus low-tar cigarettes in the 1999 Massachusetts Benchmark Study. Nicotine & Tobacco Research 2004, 6:797-807.
32. Hukkanen J., et al. Metabolism and disposition kinetics of nicotine. Pharmacological Reviews 2005, 57:79-115.
33. Irving D.W., et al. Effect of smoking on cardiac output. British Heart Journal 1963, 25:126-132.
34. Jack D.B. Factors contributing to variability in drug pharmacokinetics. III. Metabolism. J. Clin. Hosp. Pharm. 1985, 10:25-43.
35. Levy M.N., Berne R.M. Cardiovascular Physiology 1997, Mosby, St. Louis.
36. Marian C., et al. Reconciling human smoking behavior and machine smoking patterns: implications for understanding smoking behavior and the impact on laboratory studies. Cancer Epidemiology, Biomarkers & Prevention 2009, 18:3305-3320.
37. Marino D.J., et al. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice. Regulatory Toxicology and Pharmacology 2006, 45:44-54.
38. Myers M.G., et al. Cardiovascular effects of smoking. Clinical and Investigative Medicine - Medecine Clinique Et Experimentale 1986, 9:B33.
39. Nakajima M., et al. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clinical Pharmacology & Therapeutics 2000, 67:57-69.
40. Nong A., et al. Bayesian calibration of a physiologically based pharmacokinetic/pharmacodynamic model of carbaryl cholinesterase inhibition. Journal of Toxicology and Environmental Health. Part A 2008, 71:1363-1381.
41. Perry D.C., et al. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. Journal of Pharmacology and Experimental Therapeutics 1999, 289:1545-1552.
42. Plowchalk D.R., et al. A physiologically based pharmacokinetic model for nicotine disposition in the sprague-dawley rat. Toxicology and Applied Pharmacology 1992, 116:177-188.
43. Porchet H.C., et al. Pharmacodynamic model of tolerance - application to nicotine. Journal of Pharmacology and Experimental Therapeutics 1988, 244:231-236.
44. Regardh C.G. Factors contributing to variability in drug pharmacokinetics. IV. Renal excretion. J. Clin. Hosp. Pharm. 1985, 10:337-349.
45. Robinson D.E., et al. A physiologically based pharmacokinetic model for nicotine and cotinine in man. Journal of Pharmacokinetics and Biopharmaceutics 1992, 20:591-609.
46. Routledge P.A. Factors contributing to variability in drug pharmacokinetics. II. Drug distribution. J. Clin. Hosp. Pharm. 1985, 10:15-23.
47. Scherer G. Smoking behaviour and compensation: a review of the literature. Psychopharmacology (Berlin) 1999, 145:1-20.
48. Schmitt W. Corrigendum to " General approach for the calculation of tissue to plasma partition coefficients" [Toxicology in Vitro 22 (2008) 457-467]. Toxicology in Vitro 2008, 1666.
49. Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. Toxicology in Vitro 2008, 22:457-467.
50. Shiraishi K., et al. Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese. Carcinogenesis 2009, 30:65-70.
51. St.Charles F.K., et al. The linear relationship between cigarette tar and nicotine yields: regulatory implications for smoke constituent ratios. Regulatory Toxicology and Pharmacology 2011, 59:143-148.
52. Tachmes L., et al. Hemodynamic effects of smoking cigarettes of high and low nicotine content. Chest 1978, 74:243-246.
53. Teeguarden J.G., et al. Derivation of a human equivalent concentration for n-butanol using a physiologically-based pharmacokinetic model for n-butyl acetate and metabolites n-butanol and n-butyric acid. Toxicological Sciences 2005, 85:429-446.
54. Teeguarden J.G., et al. Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach. Toxicological Sciences 2005, 85:823-838.
55. Thomas C.B., Murphy E.A. Circulatory responses to smoking in healthy young men. Annals of the New York Academy of Sciences 1960, 90:266-276.
56. Timchalk C., et al. A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. Toxicological Sciences 2002, 66:34-53.
57. Timchalk C., Teeguarden J.G., Corley R.A. Quantitative risk assessment: a computational dosimetry framework for tobacco harm reduction, (2699). The Toxicologist CD - An Official Journal of the Society of Toxicology 2011, 120.
58. Tournier J.M., Birembaut P. Nicotinic acetylcholine receptors and predisposition to lung cancer. Current Opinion in Oncology 2011, 23:83-87.
59. Welling P.G., Tse F.L. Factors contributing to variability in drug pharmacokinetics. I. Absorption. J. Clin. Hosp. Pharm. 1984, 9:163-179.
60. West R.J., et al. Does switching to an ultra-low nicotine cigarette induce nicotine withdrawal effects?. Psychopharmacology (Berlin) 1984, 84:120-123.
61. WHO, 2003. Statement of principles guiding the evaluation of new or modified tobacco products. In: World Health Organization, W., (Ed.), Geneva.
62. Yamazaki H., et al. Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling. International Journal of Environmental Research and Public Health 2010, 7:3406-3421.
63. Yang J.-M., deBithizy J.D. A population pharmacokinetic model for nicotine and its application to human exposure. The Toxicologist 1995, 15.
64. Yang, J.M. et al., 1996. Physiologically-based pharmacodynamic modeling of acute cardiovascular response to repeated nicotine administration in humans. In: 35th Annual Society of Toxicology Meeting, Anaheim, CA.
65. Yang Y., et al. A Bayesian population PBPK model for multiroute chloroform exposure. Journal of Exposure Analysis and Environmental Epidemiology 2010, 20:326-341.
66. Zacny J.P., Stitzer M.L. Cigarette brand-switching: effects on smoke exposure and smoking behavior. Journal of Pharmacology and Experimental Therapeutics 1988, 246:619-627.